Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Tanimoto

Showing results (61-70 of 353) with videos related to

Pageof 36
Sort By:
The New England Journal of Medicine|March 9, 2018
Letermovir Prophylaxis for CytomegalovirusKumi Oshima, Jinichi Mori, Tetsuya Tanimoto
JAMA|October 5, 2017
Characteristics of Novel Therapeutics and Postmarket Safety EventsTetsuya Tanimoto, Jinichi Mori, Yasuo Oshima
Health Science Reports|December 20, 2023
Letter to the editor: Japan's emergency approval system under the COVID-19 pandemicYudai Kaneda, Akihiko Ozaki, Tetsuya Tanimoto
JAMA|June 21, 2017
Temporal Changes in Subsequent Malignancies Among Childhood Cancer SurvivorsTetsuya Tanimoto, Kenji Tsuda, Jinichi Mori
Annals of Internal Medicine|March 3, 2020
Vibrio vulnificus Infections From a Previously Nonendemic AreaYasuo Oshima, Tetsuya Tanimoto, Koichiro Yuji
Lancet (London, England)|January 31, 2019
Reducing road traffic accidents in BangladeshVivek Podder, Tomohiro Morita, Tetsuya Tanimoto
Clinical and Translational Science|September 11, 2023
Japan's COVID-19 treatment strategy: An examination of approved oral medicationsYuka Higuchi, Yudai Kaneda, Tetsuya Tanimoto
Investigational New Drugs|April 3, 2025
US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelinesHayase Hakariya, Akihiko Ozaki, Tetsuya Tanimoto
The New England Journal of Medicine|November 1, 2013
Treatment for high-risk smoldering myelomaKenji Tsuda, Tetsuya Tanimoto, Tsunehiko Komatsu
The New England Journal of Medicine|March 3, 2016
Lenalidomide plus Rituximab for Mantle-Cell LymphomaKenji Tsuda, Tetsuya Tanimoto, Tsunehiko Komatsu
Pageof 36

Showing results (61-70 of 353) with videos related to

Sort By:
Pageof 36
The New England Journal of Medicine|March 9, 2018
Letermovir Prophylaxis for CytomegalovirusKumi Oshima, Jinichi Mori, Tetsuya Tanimoto
JAMA|October 5, 2017
Characteristics of Novel Therapeutics and Postmarket Safety EventsTetsuya Tanimoto, Jinichi Mori, Yasuo Oshima
Health Science Reports|December 20, 2023
Letter to the editor: Japan's emergency approval system under the COVID-19 pandemicYudai Kaneda, Akihiko Ozaki, Tetsuya Tanimoto
JAMA|June 21, 2017
Temporal Changes in Subsequent Malignancies Among Childhood Cancer SurvivorsTetsuya Tanimoto, Kenji Tsuda, Jinichi Mori
Annals of Internal Medicine|March 3, 2020
Vibrio vulnificus Infections From a Previously Nonendemic AreaYasuo Oshima, Tetsuya Tanimoto, Koichiro Yuji
Lancet (London, England)|January 31, 2019
Reducing road traffic accidents in BangladeshVivek Podder, Tomohiro Morita, Tetsuya Tanimoto
Clinical and Translational Science|September 11, 2023
Japan's COVID-19 treatment strategy: An examination of approved oral medicationsYuka Higuchi, Yudai Kaneda, Tetsuya Tanimoto
Investigational New Drugs|April 3, 2025
US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelinesHayase Hakariya, Akihiko Ozaki, Tetsuya Tanimoto
The New England Journal of Medicine|November 1, 2013
Treatment for high-risk smoldering myelomaKenji Tsuda, Tetsuya Tanimoto, Tsunehiko Komatsu
The New England Journal of Medicine|March 3, 2016
Lenalidomide plus Rituximab for Mantle-Cell LymphomaKenji Tsuda, Tetsuya Tanimoto, Tsunehiko Komatsu
Pageof 36